Last reviewed · How we verify
NCT06332300
An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
Phase 2 trial testing Adebelimumab+Famitinib + FOLFIRI+Ariely in NSCLC. Withdrawn.
1 February 2025
Quick facts
| Lead sponsor | Jiangsu Province Nanjing Brain Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 February 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Adebelimumab+Famitinib + FOLFIRI+Ariely — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Jiangsu Province Nanjing Brain Hospital
Who can join
Adults 18 to 75, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06332300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Jiangsu Province Nanjing Brain Hospital trials
Trials by the same sponsor.
- NCT07317557 — Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease · NA · not yet recruiting
- NCT07480317 — TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease · NA · not yet recruiting
- NCT07323121 — 40 Hz Flickering for Insomnia in Parkinson's Disease · NA · not yet recruiting
- NCT07299240 — Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease · NA · not yet recruiting
- NCT07492472 — The Effects of Low-Intensity Music in Adolescents With Anxiety · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06332300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Nanjing Brain Hospital
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06332300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing